Rosadyn Pilot Study Results
Vascular Health Specialists, a firm dedicated to leveraging the latest dermatologic research to develop cutting-edge skin care products, announces the pilot study results of their Rosadyn nutraceutical product, which targets flushing, redness and inflammation of facial skin. The study showed significant symptom impact over the 4 week period, with more than 90% of participants reporting an improvement.
New York, NY, August 29, 2009 --(PR.com)-- Vascular Health Specialists (VHS), a firm dedicated to leveraging the latest dermatologic research to develop cutting-edge skin care products, is pleased to announce the pilot study results of their Rosadyn nutraceutical product, which targets flushing, redness and inflammation of facial skin.
Thirty-five (35) individuals who had been previously diagnosed with rosacea were selected and monitored through the first 4 weeks of an ongoing pilot study to evaluate the effect of Rosadyn on inflammatory skin symptoms. Participants took the daily-recommended dosage of Rosadyn and reported their progress via weekly online surveys conducted by the firm.
Findings:
Participants reported improvement in a range of symptoms, most notably in the areas of flushing, redness and skin sensitivity. Highlights of the results by symptom are detailed below:
Flushing and Redness:
- 94% of participants reported a reduction in facial flushing with an average reduction level of 46.0%.
- 89% of participants reported a reduction in facial redness with an average reduction level of 44.5%.
- 66% of participants reported a reduction in broken blood vessels with an average reduction level of 39.5%.
- 60% of participants reported a reduction in facial swelling with an average reduction level of 38.0%.
Skin Sensitivity:
- 91% of participants reported a reduction in overall skin discomfort with an average reduction level of 51.3%.
- 89% of participants reported a reduction in hyper-sensitive skin with an average reduction level of 50.9%.
- 89% of participants reported a reduction in burning and stinging sensations with an average reduction level of 50.6%.
Papules and Pustules:
- 63% of participants reported a reduction in inflammatory papules (small red bumps) with an average reduction level of 38.6%.
- 31% of participants reported a reduction in inflammatory pustules (red bumps with pus) with an average reduction level of 29.5%.
Other Symptom Improvements:
- 91% of participants reported a reduction in anxiety during rosacea flares and triggers with an average reduction level of 48.0%.
- 51% of participants reported a reduction in global ocular rosacea symptoms with an average reduction level of 43.3%.
Side Effects:
Participants were also asked to report any side effects associated with Rosadyn usage. The weekly survey included both a text box for participants to report any side effects in their own words, as well as a multiple choice question which asked testers to rate the level of any adverse reactions on a scale of 1-10, ranging from None, Mild, Moderate, to Severe.
In total, 89% of respondents reported no side effects at all. Of the remaining 11%, all reported effects were in the Mild range. There were no reports of any side effects at the Moderate or Severe level.
Overall Satisfaction:
To gauge overall satisfaction with Rosadyn usage, participants were asked to rate the overall status of their rosacea symptoms after Rosadyn compared to pre-test levels. In total, 91% of testers reported an improvement in the overall status of their rosacea with an average improvement level of 49%. Moreover, in response to a question of whether participants would recommend the product to fellow rosacea sufferers, 75% indicated they would.
According to Dr. Geoffrey Nase, Ph.D, VHS’s founder and developer of Rosadyn, the results surpassed the expectations of the team, “While we certainly had faith that the pharmaceutical grade ingredients selected would target key symptoms, we were surprised at the speed and breadth of the reported improvements. We were particularly encouraged by the overall reduction in flushing, as this is an inherently unresponsive symptom. The pathophysiology behind such conditions involves months or years of chronic inflammation and cellular damage that usually takes time to reverse and normalize, so these findings exceeded our expectations. That said, the importance of continued supplementation must be emphasized as inflammatory skin symptoms often require several skin renewal cycles in order to maintain a healthy skin state.”
Dr. Bitter, Sr., a partner in VHS and collaborator on Rosadyn development, commented on the results, “It was particularly rewarding to see the heartfelt testimonials and gratitude from participants who have struggled with the condition for years with only negligible improvement at best.”
Deep Skin Inflammation and Skin Renewal:
The Rosadyn Pilot study will continue to monitor the progress of testers at the two, three and six month periods. Early results indicate steady and continued improvement past the 4-week mark by most testers, highlighting the fact that the desired results may require at least 3 months (2 full skin-renewal cycles). More comprehensive testing of the affects on Rosadyn's affect on rosacea symptoms are currently under development by Vascular Health Specialists. Additional Pilot Study details will be published shortly on the Rosadyn.com website.
About Vascular Health Specialists:
Vascular Health Specialists (VHS) is a firm dedicated to leveraging the latest dermatologic research to develop cutting edge products for rosacea and other skin conditions. Comprised of a team of professionals with backgrounds in medicine, research, business and skin care product development, VHS works closely with leading laboratories and nutraceutical manufacturers to remain at the forefront of novel skin treatments.
For more information, please visit the company website at: http://www.rosadyn.com
###
Thirty-five (35) individuals who had been previously diagnosed with rosacea were selected and monitored through the first 4 weeks of an ongoing pilot study to evaluate the effect of Rosadyn on inflammatory skin symptoms. Participants took the daily-recommended dosage of Rosadyn and reported their progress via weekly online surveys conducted by the firm.
Findings:
Participants reported improvement in a range of symptoms, most notably in the areas of flushing, redness and skin sensitivity. Highlights of the results by symptom are detailed below:
Flushing and Redness:
- 94% of participants reported a reduction in facial flushing with an average reduction level of 46.0%.
- 89% of participants reported a reduction in facial redness with an average reduction level of 44.5%.
- 66% of participants reported a reduction in broken blood vessels with an average reduction level of 39.5%.
- 60% of participants reported a reduction in facial swelling with an average reduction level of 38.0%.
Skin Sensitivity:
- 91% of participants reported a reduction in overall skin discomfort with an average reduction level of 51.3%.
- 89% of participants reported a reduction in hyper-sensitive skin with an average reduction level of 50.9%.
- 89% of participants reported a reduction in burning and stinging sensations with an average reduction level of 50.6%.
Papules and Pustules:
- 63% of participants reported a reduction in inflammatory papules (small red bumps) with an average reduction level of 38.6%.
- 31% of participants reported a reduction in inflammatory pustules (red bumps with pus) with an average reduction level of 29.5%.
Other Symptom Improvements:
- 91% of participants reported a reduction in anxiety during rosacea flares and triggers with an average reduction level of 48.0%.
- 51% of participants reported a reduction in global ocular rosacea symptoms with an average reduction level of 43.3%.
Side Effects:
Participants were also asked to report any side effects associated with Rosadyn usage. The weekly survey included both a text box for participants to report any side effects in their own words, as well as a multiple choice question which asked testers to rate the level of any adverse reactions on a scale of 1-10, ranging from None, Mild, Moderate, to Severe.
In total, 89% of respondents reported no side effects at all. Of the remaining 11%, all reported effects were in the Mild range. There were no reports of any side effects at the Moderate or Severe level.
Overall Satisfaction:
To gauge overall satisfaction with Rosadyn usage, participants were asked to rate the overall status of their rosacea symptoms after Rosadyn compared to pre-test levels. In total, 91% of testers reported an improvement in the overall status of their rosacea with an average improvement level of 49%. Moreover, in response to a question of whether participants would recommend the product to fellow rosacea sufferers, 75% indicated they would.
According to Dr. Geoffrey Nase, Ph.D, VHS’s founder and developer of Rosadyn, the results surpassed the expectations of the team, “While we certainly had faith that the pharmaceutical grade ingredients selected would target key symptoms, we were surprised at the speed and breadth of the reported improvements. We were particularly encouraged by the overall reduction in flushing, as this is an inherently unresponsive symptom. The pathophysiology behind such conditions involves months or years of chronic inflammation and cellular damage that usually takes time to reverse and normalize, so these findings exceeded our expectations. That said, the importance of continued supplementation must be emphasized as inflammatory skin symptoms often require several skin renewal cycles in order to maintain a healthy skin state.”
Dr. Bitter, Sr., a partner in VHS and collaborator on Rosadyn development, commented on the results, “It was particularly rewarding to see the heartfelt testimonials and gratitude from participants who have struggled with the condition for years with only negligible improvement at best.”
Deep Skin Inflammation and Skin Renewal:
The Rosadyn Pilot study will continue to monitor the progress of testers at the two, three and six month periods. Early results indicate steady and continued improvement past the 4-week mark by most testers, highlighting the fact that the desired results may require at least 3 months (2 full skin-renewal cycles). More comprehensive testing of the affects on Rosadyn's affect on rosacea symptoms are currently under development by Vascular Health Specialists. Additional Pilot Study details will be published shortly on the Rosadyn.com website.
About Vascular Health Specialists:
Vascular Health Specialists (VHS) is a firm dedicated to leveraging the latest dermatologic research to develop cutting edge products for rosacea and other skin conditions. Comprised of a team of professionals with backgrounds in medicine, research, business and skin care product development, VHS works closely with leading laboratories and nutraceutical manufacturers to remain at the forefront of novel skin treatments.
For more information, please visit the company website at: http://www.rosadyn.com
###
Contact
Vascular Health Specialists
Dr. Geoffrey Nase
877-722-3050
www.rosadyn.com
Dr. Geoffrey Nase
877-722-3050
www.rosadyn.com
Contact
Categories